Pharmaceutical Technology

OCTOBER 17, 2023

SpliceBio will license Spark Therapeutics’ propriety protein splicing platform to develop a gene therapy for renal disease.

Gene Therapy 246

Gene Therapy Gene Licensing Licensing 246

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

NOVEMBER 2, 2022

UK-based company Ubiquigent has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture and further identification of protein ubiquitylation sites in cell and tissue samples. .

Licensing 52

Licensing Licensing Protein Antibody 52

BioTech 365

JULY 13, 2021

Worldwide Targeted Protein Degradation Industry to 2030 – Several Technology Developers Involved in High-value Licensing Deals – ResearchAndMarkets.com Worldwide Targeted Protein Degradation Industry to 2030 – Several Technology Developers Involved in High-value Licensing Deals – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Licensing 40

Licensing Licensing Protein Development 40

BioPharma Reporter

MARCH 27, 2023

The biotech is launched with an antibody-based protein degradation platform, with technology licensed from UCSF.

Protein 52

Protein Licensing Licensing Antibody 52

BioTech 365

MARCH 30, 2021

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to … (..)

Licensing 40

Licensing Licensing Protein 40

BioPharma Reporter

APRIL 18, 2023

Dyadic extends its licensing agreement with Rubic for the use of its C1-cell protein expression platform.

Licensing 52

Licensing Licensing Protein Vaccination 52

BioTech 365

FEBRUARY 2, 2021

SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice Data supports the Company’s approach to COVID-19 vaccine development TAMPA, Fla.–(BUSINESS

Licensing 40

Licensing Licensing Protein Vaccination 40

pharmaphorum

NOVEMBER 15, 2022

Their earlier partnership , signed in 2020, covered small molecule drugs directed at SLC transporters, a class of more than 450 human membrane proteins that are gatekeepers for controlling the movement of metabolites in and out of cells and organs. The post Roche deepens ties with Jnana with a second licensing deal appeared first on.

Licensing 102

Licensing Licensing Protein Genetics 102

BioSpace

NOVEMBER 7, 2022

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech to develop therapeutic antibodies or small molecules that target membrane proteins.

Protein 60

Protein Licensing Licensing Antibody 60

Bio Pharma Dive

SEPTEMBER 4, 2020

The licensing deal hands AbbVie exclusive rights to a drug that targets CD47, a protein which has caught the attention of other large drugmakers like Gilead and Celgene.

Licensing 261

Licensing Licensing Drugs Protein 261

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 Lilly has bought into Lycia’s lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological disease and pain.

Protein 69

Protein Licensing Licensing Drugs 69

pharmaphorum

NOVEMBER 23, 2021

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The post Chinese tech giant Baidu licenses mRNA algorithm to Sanofi appeared first on. Specific financial terms have not been disclosed.

Licensing 102

Licensing Licensing Vaccination Vaccine 102

Pharmaceutical Technology

APRIL 13, 2023

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Production 279

Production Vaccination Vaccine Protein 279

pharmaphorum

NOVEMBER 2, 2021

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. The post UK biotech Dunad inks $1.3bn Novartis deal for its protein degraders appeared first on.

Protein 90

Protein Licensing Licensing Drugs 90

Bio Pharma Dive

MAY 12, 2022

The pharma will pay $90 million to license BridgeBio's experimental candidate, joining a lengthening list of large drugmakers aiming to treat cancer by blocking a protein called SHP2.

Licensing 158

Licensing Licensing Protein Drugs 158

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The post Lantheus on POINT in radio-oncology with $2bn licensing deal appeared first on. billion in milestone payments.

Licensing 52

Licensing Licensing FDA Approval Trials 52

BioTech 365

AUGUST 11, 2021

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and … Continue reading →

Licensing 40

Licensing Licensing Protein Vaccination 40

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Protein 52

Protein Licensing Licensing Containment 52

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down. billion partnership last week.

Protein 52

Protein Genome Genomics Drugs 52

XTalks

JULY 19, 2022

The two-dose protein-based, adjuvanted vaccine has been authorized for use in adults 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. Nevertheless, 77 percent of those polled said that even if a protein-based COVID shot were authorized in the US, they still would not get it.

Vaccination 94

Vaccination Vaccine Protein Clinical Trials 94

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

FEBRUARY 24, 2022

Viral or bacterial infections, or airway irritants can damage lung cells, causing them to release damage associated molecular pattern (DAMP) molecules that attach to and activate the receptor for advanced glycation endproducts (RAGE) protein found on a cell’s membrane.

Licensing 64

Licensing Licensing Development Drugs 64

BioSpace

SEPTEMBER 16, 2020

Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment.

Licensing 142

Licensing Licensing Protein 142

Delveinsight

AUGUST 18, 2020

Sanofi had earlier licensed-in Principia’s experimental multiple sclerosis treatment ‘168; the late-stage pemphigus treatment Rilzabrutinib; and PRN473, a topical BTK inhibitor. USD 475 Million Deal: BMS Inks An A Global License Deal With Dragonfly For Immunotherapy Program .

Licensing 52

Licensing Licensing Protein Antibody 52

pharmaphorum

DECEMBER 7, 2021

Eplontersen – previously known as IONIS-TTR-L RX – is designed to switch off the production of transthyretin (TTR), a protein which builds up in the disease to toxic levels causing heart problems (cardiomyopathy) and nerve damage (polyneuropathy). billion in milestones depending on sales levels if the antisense-based drug reaches the market.

Licensing 59

Licensing Licensing Drugs Marketing 59

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

BioTech 365

OCTOBER 14, 2020

License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools Technology will be integrated into Rentschler Biopharma’s in-house process with a fast, cost-effective, and stable platform to complement existing CLD offering LAUPHEIM, Germany & … Continue reading (..)

Licensing 52

Licensing Licensing Development Protein 52

Pharmaceutical Technology

OCTOBER 21, 2022

DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing.

Antibody 217

Antibody Protein Licensing Licensing 217

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers.

Licensing 40

Licensing Licensing Life Science Development 40

Pharma Times

OCTOBER 14, 2020

Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development

Licensing 65

Licensing Licensing Protein Development 65

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. CMG901 is being developed for the treatment of solid tumours that express the cell surface protein Claudin 18.2, i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, and consists of an anti-Claudin 18.2

Licensing 40

Licensing Licensing Antibody Drugs 40

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells.

Licensing 52

Licensing Licensing Drugs Development 52

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

DECEMBER 6, 2022

According to the agreement, ExpreS 2 ion will hold the exclusive right for licensing the CMV vaccine candidate under a possible development and commercialisation agreement. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52